Search

Your search keyword '"Steurer, M."' showing total 158 results
Start Over Author "Steurer, M." Search Limiters Full Text
158 results on '"Steurer, M."'

3. A megawatt-scale power hardware-in-the-loop simulation setup for motor drives

Author

Steurer, M., Edrington, C.S., Sloderbeck, M., Wei Ren, and Langston, J.

Subjects
Digital signal processors -- Usage, Electric current converters -- Usage, Electric motors -- Design and construction, Power electronics -- Analysis, Digital signal processor, Electric current converter, Business, Computers, Electronics, Electronics and electrical industries
Published
2010

4. Power hardware-in-the-loop testing of a YBCO coated conductor fault current limiting module

Author

Schacherer, C., Langston, J., Steurer, M., and Noe, M.

Subjects
Electrical cables -- Fault location, Electrical cables -- Analysis, Superconductive devices -- Composition, Superconductive devices -- Design and construction, Yttrium -- Magnetic properties, Yttrium -- Electric properties, Barium compounds -- Electric properties, Barium compounds -- Magnetic properties, Copper oxide superconductors -- Magnetic properties, Copper oxide superconductors -- Electric properties, Business, Electronics, Electronics and electrical industries
Published
2009

7. Hardware-in-the-loop investigation of rotor heating in a 5 MW HTS propulsion motor

Author

Steurer, M., Woodruff, S., Baldwin, T., Boenig, H., Bogdan, F., Fikse, T., Sloderbeck, M., and Snitchler, G.

Subjects
Rotors -- Design and construction, High temperature superconductors -- Design and construction, Electric power systems -- Electric losses, Electric power systems -- Analysis, Business, Electronics, Electronics and electrical industries
Abstract

The potential rotor heating in a 5 MW High Temperature Superconducting (HTS) Technology Demonstrator prototype motor is examined. Findings reveal the observation of measurable additional rotor heating with sea-state level-5 and motor speeds above 50 percent.

Published
2007

8. A nitrogen gas cooled, hybrid, high temperature superconducting fault current limiter

Author

Steurer, M., Brechna, H., and Frohlich, K.

Subjects
High temperature superconductivity -- Research, Limiter circuits -- Design and construction, Business, Electronics, Electronics and electrical industries
Abstract

A concept for a nitrogen gas cooled hybrid, high temperature superconducting fault current limiter is proposed.

Published
2000

12. Retrospective cohort study of all deaths among infants born between 22 and 27 completed weeks of gestation in Switzerland over a 3-year period

Author

Berger, T M, Steurer, M A, Bucher, H U, Fauchère, J C, Adams, M, Pfister, R E, Baumann-Hölzle, R, Bassler, D, Swiss Neonatal End-of-Life Study Group, University of Zurich, and Berger, T M

Subjects
Parents, Pediatrics, medicine.medical_specialty, Decision Making, 610 Medicine & health, Infant, Premature, Diseases, 2700 General Medicine, live birth, 03 medical and health sciences, Advance Care Planning, 0302 clinical medicine, end-of-life decision-making, 030225 pediatrics, Intensive care, Intensive Care Units, Neonatal, Infant Mortality, medicine, Humans, 030212 general & internal medicine, Retrospective Studies, ddc:618, business.industry, extremely low gestational age neonates, Research, Delivery room, Infant, Newborn, Gestational age, Infant, Retrospective cohort study, Paediatrics, General Medicine, 10027 Clinic for Neonatology, Life support, Infant, Extremely Premature, Practice Guidelines as Topic, Quality of Life, Gestation, stillbirth, Level iii, Live birth, business, Medical Futility, Switzerland, redirection of care
Abstract

Objectives The aim of this research is to assess causes and circumstances of deaths in extremely low gestational age neonates (ELGANs) born in Switzerland over a 3-year period. Design Population-based, retrospective cohort study. Setting All nine level III perinatal centres (neonatal intensive care units (NICUs) and affiliated obstetrical services) in Switzerland. Patients ELGANs with a gestational age (GA)

Published
2017

15. Chromothripsis in acute myeloid leukemia: Biological features and impact on survival

Author

Fontana, M C, primary, Marconi, G, additional, Feenstra, J D M, additional, Fonzi, E, additional, Papayannidis, C, additional, di Rorá, A G L, additional, Padella, A, additional, Solli, V, additional, Franchini, E, additional, Ottaviani, E, additional, Ferrari, A, additional, Baldazzi, C, additional, Testoni, N, additional, Iacobucci, I, additional, Soverini, S, additional, Haferlach, T, additional, Guadagnuolo, V, additional, Semerad, L, additional, Doubek, M, additional, Steurer, M, additional, Racil, Z, additional, Paolini, S, additional, Manfrini, M, additional, Cavo, M, additional, Simonetti, G, additional, Kralovics, R, additional, and Martinelli, G, additional

Published
2017
Full Text
View/download PDF

17. Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study

Author

Ninkovic, M., Fiegl, M., Mian, M., Mondello, P., Kocher, F., Waldthaler, C., Verdorfer, I., Steurer, M., Gastl, G., and Andreas Pircher

Subjects
Bendamustine, chemotherapy, chronic lymphocytic leukemia (CLL), immunotherapy, rituximab, Antineoplastic Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Disease-Free Survival, Cohort Studies, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Multivariate Analysis, Bendamustine Hydrochloride, Humans, Rituximab
Abstract

Bendamustine is an established treatment option in chronic lymphocytic leukemia (CLL) and frequently used in Austria and Italy. Therefore, we analyzed 100 unselected, consecutive patients with CLL (treatment-naïve and relapsed/refractory) receiving bendamustine in a real-life setting. Most patients were treated with bendamustine in combination with rituximab (BR). However, bendamustine monotherapy was additionally evaluated. Patients treated with BR had a significantly higher overall response rate of 76% (complete response=22%) when compared to those treated solely with bendamustine (overall response rate=50%; complete response=13%). Overall survival (OS) and progression -ree survival (PFS) were significantly lower in the bendamustine-treated group (OS=14.3 months; PFS=8.3 months) compared to the BR group (OS=42.7; PFS=22.5 months; both p0.001). In multivariate analysis, patients with a good cytogenetic risk and those receiving BR had a significantly better OS. Grade 3/4 hematological complications were seen in 32% of the patients. Hence, bendamustine, especially in combination with rituximab, is an effective therapy with manageable toxicity for non-selected patients with CLL including those pre-treated with fludarabine and the elderly.

Published
2015

19. Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials

Author

Bauduer, M., Gribben, J., Herrmann, R., Thiel, E., Rai, K., Larson, R., Ferrara, F., Barnard, J., Pearce, H., Taylor, C., Brillant, B., Steurer, M., Weingart, O., Flinn, W., Funkhouser, A., Nallman, M., Sun, Z., Jakšić, Branimir, Suciou, S., Chevret, S., Dighiero, G., Leporrier, M., Frankel, S.R., Sirard, C., Hillmen, P., Trehu, B., Felder, M., Busch, R., Eichorst, B., Mallek, M., Stilgenbauer, S., Pangalis, G., Bezares, R., van Oers, M.H.J., van Putten, W., Gobbi, M., Spriano, M., Mabed, M., Catovsky, D., Richards, S., Wade, R., Abdelhamid, T., Dearden, C., Knauf, W., Blonski, J., Jamroziak, K., Robak, T., Mauro, F., Hiddeman, W., Johnson, S.A., Longthorne, G., Rummel, M.J., Juliusson, G., Pulluqui, P., Zinzani, P.L., Pozzato, G., Reynolds, C, Furman, R.R., Durrant, J., Elphinstone, P., Evans, V., Gettins, .L, Hicks, C., James, S., Clarke, M., MacKinnon, L., McHugh, T.M., Morris, P., Read, S., Gregory, C., Pozzato, Gabriele, Bauduer M, Gribben J, Herrmann R, Thiel E, Rai K, Larson R, Ferrara F, Barnard J, Pearce H, Taylor C, Brillant C, Steurer M, Weingart O, Flinn IW, Funkhouser A, Tallman M, Sun Z, Jaksic B, Suciu S, Chevret S, Dighiero G, Leporrier M, Frankel SR, Sirard C, Hillmen P, Trehu B, Felder M, Busch R, Eichhorst B, Hallek M, Stilgenbauer S, Pangalis G, Bezares R, van Oers MH, van Putten W, Gobbi M, Spriano M, Mabed M, Catovsky D, Richards S, Wade R, Abdelhamid T, Dearden C, Knauf W, Blonski J, Jamroziak K, Robak T, Mauro F, Hiddeman W, Johnson SA, Longthorne G, Juliusson G, Pulluqi P, Zinzani PL, Pozzato G, Oncology US, Reynolds C, Furman RR, Durrant J, Elphinstone P, Evans V, Gettins L, Hicks C, James S, Clarke M, MacKinnon L, McHugh TM, Morris P, Read S, and Gregory C. CLL Trialists’ Collaborative Group

Subjects
Oncology, medicine.medical_specialty, review, Purine analogue, chronic lymphocytic leukemia, fludarabine, clinical trial, Pharmacology, Disease-Free Survival, combination therapy, purine analog, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Progression-free survival, Cladribine, Antineoplastic Agents, Alkylating, Chlorambucil, business.industry, Hematology, Odds ratio, Leukemia, Lymphocytic, Chronic, B-Cell, Fludarabine, Clinical trial, Treatment Outcome, CLL, cyclophosphamide, Purines, Original Articles and Brief Reports, business, Untreated Chronic Lymphocytic Leukemia, medicine.drug
Abstract

Background. A systematic review of purine analogs revealed heterogeneity between trials in treatment effects on response and progression free survival, but not survival, perhaps partly due to variations in analysis methods. In addition, combination treatments required evaluation. Design and Methods. Individual patient data were sought for all randomized trials in untreated chronic lymphocytic leukemia which involved a purine analog, but not including antibody therapies. Results. Sixteen trials were found, addressing seven comparisons. Eight trials, with 2753 patients, showed that single agent purine analog improved progression free survival (Odds ratio = 0.71; 95% confidence interval =0.63-0.79). Heterogeneity remained substantial. Three trials, with 1403 patients, showed that progression free survival was further improved by the addition of cyclophosphamide (Odds ratio = 0.54; 0.47-0.62). Fewer data were available on the addition of other drugs to purine analog, and none showed clear benefit. Two trials, with 544 patients, suggested cladribine improved progression free survival compared to fludarabine (Odds ratio = 0.77; 0.63-0.95). No differences were seen in overall survival for any comparisons. Conclusions. Purine analogs, particularly combined with cyclophosphamide, significantly improve progression free survival but not survival. Some groups, such as the elderly, may not see the same benefits and maximising doses may be important for all treatments, including chlorambucil. Longer follow-up, consistent definitions and detailed reporting of trials should be encouraged.

Published
2012

20. A New GPS-based Digital Protection System for Smart Grids in Loop Structure.

Author

Liu, X., Steurer, M., and Yu, M.

Subjects
SMART power grids, MICROCONTROLLERS, GLOBAL Positioning System, DIGITAL technology, ETHERNET
Abstract

This paper presents a new digital protection system to solve the protection challenges in future smart grids, i.e., fast protection and fault isolation in a loop-structured system with limited magnitude of fault current. The new system combines two protection algorithms, i.e., a differential protection as the primary algorithm and an overcurrent protection as the backup one. The new system uses real-time Ethernet and digital data acquisition techniques to overcome the restriction on data transmission over large grids. The current measurements at different locations are time-synchronized by GPS clocks, and then transmitted to a central computer via the Ethernet. As opposed to digital relays which often contain PMU functionality nowadays, this approach uses time stamps on the instantaneous current values. We build a prototype of the new system on a test-bed. The results from simulations and experiments have demonstrated that the protection system achieves fast and accurate protection. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

24. A novel approach to power quality assessment: real time hardware-in-the-loop test bed

Author

Liu, Y., Steurer, M., and Ribeiro, P.

Subjects
Electric current converters -- Research, Electric power transmission -- Research, Electric current converter, Business, Computers, Electronics, Electronics and electrical industries
Abstract

A novel approach to power quality assessment based on real-time (RT) hardware-in-the-loop (HIL) simulation is proposed. The RT-HIL platform is being used for power quality studies of NAVY all-electric ships. The sensitivity for power quality deviations of a variable speed drive controller card was tested in the platform. The successful experiment has contributed to the conceptual design of a universal power quality test bed, which would have the function of testing the immunity of electric components and equipment and the consequent impact on ac distribution systems. Index Terms--All-electric ship, hardware-in-the-loop simulation, harmonics, power quality, voltage sags.

Published
2005

26. eine Analyse von über 1600 präparierten Nerven

Author

Steurer, M, Denk, D, Schneider, B, Passler, C, Niederle, B, and Bigenzahn, W

Subjects
ddc: 610
Abstract

Einleitung: Eine Strategie zur Veringerung von pemanenten Paresen des N. laryngeus recurrens (RLNP) in der Schildrüsenchirurgie ist die obligate Nervenpräparation. Der Effekt des intraoperativen Neuromonitorings (IONM) des N. laryngeus reccurrens (RLN) ist noch immer unklar.Methoden: Es wurden 913 Patienten mit Hemithyroidectomie oder totaler Thyroidektomie mit 1602 gefährdeten Nerven (NAR) mittels Laryngoskopie und Videostroboskopie prea- und postoperativ prospektiv untersucht. In jedem Fall wurde eine langstreckige Präparation des RLN vorgenommen. Dabei wurde kein IONM eingesetzt. Benigne (BT) (1014 NAR) und maligne Schilddrüsenerkrankungen (MT) (578 NAR) wurden getrennt analysiert. Eine RLNP wurde nicht vor 2 Jahren ihres Bestehens als permanent bezeichnet.Ergebnisse: Es wurden 2,6% und 4,5% temporäre RLNPs je Nerv in der BT bzw. MT Gruppe identifiziert, und nur 0,3% und 0,9% an permanenten RLNPs in den jeweiligen Gruppen.Schlussfolgerungen: In den meisten Studien mit Nervenpräparation war die Rate an RLNPs (temporär und permanent) niedriger als in solchen ohne Durchführung einer Nervenpräparation. Hingegen zeigten Studien mit IONM keine Verbesserung der Rate. Eine obligate Nervenpräparation verringert also die Anzahl permanenter RLNP wirksam. Neben der indirekten Laryngoskopie sollte bei allen Patienten mit nicht eindeutig normaler beidseitiger Larynxfunktion und Stimmqualität unbedingt eine Videostroboskopie durchgeführt werden, um Fehldiagnosen zu vermeiden.

Published
2004

30. Interfacing Issues in Multi-Domain Simulation Tools

Author

Faruque, M. O., primary, Dinavahi, V., additional, Steurer, M., additional, Monti, A., additional, Strunz, K., additional, Martinez, J. A., additional, Chang, G. W., additional, Jatskevich, J., additional, Iravani, R., additional, and Davoudi, A., additional

Published
2012
Full Text
View/download PDF

31. Performance of 2G HTS Tapes in Sub-Cooled LN2 for Superconducting Fault Current Limiting Applications

Author

Llambes, J. C., primary, Hazelton, D., additional, Duval, J., additional, Albertini, M., additional, Repnoy, S., additional, Selvamanickam, V., additional, Majkic, G., additional, Kesign, I., additional, Langston, J., additional, Steurer, M., additional, Bogdan, F., additional, Hauer, J., additional, Crook, D., additional, Ranner, S., additional, Williams, T., additional, and Coleman, M., additional

Published
2011
Full Text
View/download PDF

32. Interfacing Issues in Real-Time Digital Simulators

Author

Ren, W., primary, Sloderbeck, M., additional, Steurer, M., additional, Dinavahi, V., additional, Noda, T., additional, Filizadeh, S., additional, Chevrefils, A. R., additional, Matar, M., additional, Iravani, R., additional, Dufour, C., additional, Belanger, J., additional, Faruque, M.O., additional, Strunz, K., additional, and Martinez, J. A., additional

Published
2011
Full Text
View/download PDF

48. Detailed Modeling of Superconducting Magnetic Energy Storage (SMES) System.

Author

Chen, L., Liu, L., Arsoy, A. B., Ribeiro, P. F., Steurer, M., and Iravani, M. R.

Subjects
MAGNETIC energy storage, ELECTRIC power, ENERGY storage, ENGINEERING, ELECTRICAL engineering
Abstract

This paper presents a detailed model for simulation of a Superconducting Magnetic Energy Storage (SMES) system. SMES technology has the potential to bring real power storage characteristic to the utility transmission and distribution systems. The principle of SMES system operation is reviewed in this paper. To understand transient and dynamic performance of a SMES system, a detailed SMES system benchmark model is given with extensive simulation results. This system is demonstrated using an electromagnetic transient program—PSCAD/EMTDC. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results